共 108 条
[1]
Stovner LJ(2018)Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 Lancet Neurol 17 954-976
[2]
Nichols E(2003)The family impact of migraine: population-based studies in the USA and UK Cephalalgia 23 429-440
[3]
Steiner TJ(2007)Migraine prevalence, disease burden, and the need for preventive therapy Neurology 68 343-349
[4]
Lipton RB(2013)Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II) Headache 53 644-655
[5]
Bigal ME(2019)Current and emerging evidence-based treatment options in chronic migraine: a narrative review J Headache Pain 20 92-229
[6]
Kolodner K(2018)Pharmacologic prevention of migraine: a narrative review of the state of the art in 2018 Headache 58 218-1088
[7]
Stewart WF(2018)Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial JAMA Neurol 75 1080-1454
[8]
Liberman JN(2018)Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial Cephalalgia 38 1442-1408
[9]
Steiner TJ(2019)European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention J Headache Pain 20 6-1235
[10]
Lipton RB(2007)The impact of topiramate on health-related quality of life indicators in chronic migraine Headache 47 1398-e517